Searches , social queries for SINTILIMAB
Search references for SINTILIMAB. Phrases containing SINTILIMAB
See searches and references containing SINTILIMAB!
Search references for SINTILIMAB. Phrases containing SINTILIMAB
See searches and references containing SINTILIMAB!SINTILIMAB
Medication to treat Hodgkin's disease
Sintilimab, sold under the brand Tyvyt among others, is a medication used to treat Hodgkin's disease, and has been approved in China. It is a fully human
Sintilimab
American pharmaceutical company
patients. On 18 May 2021, the FDA accepted Lilly's application for Tyvyt (sintilimab), in combination with Lilly's own Alimta (pemetrexed) and platinum chemotherapy
Eli_Lilly_and_Company
Chinese Biopharmaceutical Company
Exchange. The offering raised $421 million. In December 2018, Innovent's Sintilimab was approved in China. In 2020, Eli Lilly paid $200 million upfront and
Innovent_Biologics
Class of anticancer drugs
for the treatment of relapsed or refractory classical Hodgkin lymphoma. Sintilimab (IBI308), a human anti-PD-1 antibody developed by Innovent Biologics and
PD-1_and_PD-L1_inhibitors
Chinese university professor (1964)
which is the world's first oncolytic virus product; Tyvyt (generic name: sintilimab), which is the domestically developed PD-1 antibody jointly developed
Yu_Dechao
Sjögren's disease Ibalizumab Trogarzo mab humanized CD4 Y HIV infection Sintilimab human PD-1 squamous cell non-small cell lung cancer Ibritumomab tiuxetan
List of therapeutic monoclonal antibodies
List_of_therapeutic_monoclonal_antibodies
Tumor originating in adipose (fat) tissue
unresectable MLS. A phase II clinical trial is recruiting patients to evaluate sintilimab (a human IgG4 monoclonal antibody directed against the programmed cell
Liposarcoma
travel, tourism, insurance
SINTILIMAB
SINTILIMAB
SINTILIMAB
SINTILIMAB
SINTILIMAB
SINTILIMAB
SINTILIMAB
SINTILIMAB
SINTILIMAB
travel, tourism, insurance